Valuation: Avicanna Inc.

Market Cap 15.15M 10.92M 9.41M 8.91M 8.07M 1.04B 15.23M 106M 40.69M 531M 41.01M 40.11M 1.68B P/E 2024
-8.43x
P/E 2025 -9.36x
Enterprise Value 14.87M 10.72M 9.23M 8.74M 7.93M 1.02B 14.94M 104M 39.93M 521M 40.25M 39.37M 1.65B EV / Sales 2024
1.31x
EV / Sales 2025 1.03x
Free-Float
78.71%
Yield 2024 *
-
Yield 2025 -
1 day-4.35%
1 week-15.38%
Current month-15.38%
1 month-15.38%
3 months-12.00%
6 months-37.14%
Current year-51.11%
1 week 0.1
Extreme 0.1
0.12
1 month 0.1
Extreme 0.1
0.14
Current year 0.1
Extreme 0.095
0.24
1 year 0.1
Extreme 0.095
0.3
3 years 0.1
Extreme 0.095
0.6
5 years 0.1
Extreme 0.095
1
10 years 0.1
Extreme 0.095
7.4
Manager TitleAgeSince
Sales & Marketing - 01/05/2015
Chief Executive Officer 39 26/11/2016
Director of Finance/CFO - 15/09/2025
Director TitleAgeSince
Chairman 39 26/11/2016
Director/Board Member - 22/10/2018
Director/Board Member - 01/01/2026
Date Insider Type Main position Quantity % Market Cap. Importance
12/06/26 Sell

Director

333,000 0.2647%
27/05/26 Buy

Director

160,000 0.1272%
26/05/26 Buy

Director

150,000 0.1192%
Change 5-day change 1-year change 3-year change Capi.($)
-4.35%-15.38%-59.26%-71.05% 10.92M
+0.79%-4.35%-2.01%+9.59% 45.48B
-0.86%-2.25%+338.64%+522.58% 43.68B
+0.81%+2.04%+42.23%+24.20% 43.09B
+1.91%+0.36%+6.17%+77.71% 39.4B
-1.44%-5.26%+8.97%+39.76% 31.91B
-0.59%-3.12% - - 17.31B
+0.78%+0.13%+19.19%+111.28% 16.4B
+2.52%+1.23%+14.90%+31.49% 14.24B
-2.02%-3.00%+78.89%+31.08% 13.28B
Average -0.24%-4.42%+49.75%+86.29% 26.48B
Weighted average by Cap. +0.29%-3.50%+75.24%+126.55%

Financials

2024 2025
Net sales 25.46M 18.35M 15.81M 14.97M 13.57M 1.75B 25.59M 178M 68.38M 892M 68.92M 67.41M 2.82B 25.48M 18.37M 15.82M 14.98M 13.58M 1.75B 25.61M 178M 68.43M 893M 68.98M 67.46M 2.82B
Net income -3.62M -2.61M -2.25M -2.13M -1.93M -249M -3.64M -25.27M -9.72M -127M -9.79M -9.58M -401M -2.76M -1.99M -1.71M -1.62M -1.47M -190M -2.77M -19.27M -7.41M -96.67M -7.47M -7.31M -305M
Net Debt -339K -244K -210K -199K -181K -23.33M -341K -2.37M -910K -11.87M -917K -897K -37.51M -281K -202K -174K -165K -150K -19.33M -282K -1.96M -754K -9.83M -760K -743K -31.07M
Logo Avicanna Inc.
Avicanna Inc. is a commercial-stage international biopharmaceutical company. It focuses on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Its products and services are grouped into four main categories, such as medical cannabis products; MyMedi.ca medical cannabis platform; pharmaceutical pipeline; and active pharmaceutical ingredients. The formulary of proprietary medical cannabis products is marketed under the RHO Phyto brand and offers a range of scientifically driven formulations in a variety of products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca offers a diverse portfolio of products and bilingual pharmacist-led patient support programs. It has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. Trunerox is its oral formulation.
Employees
112
Date Price Change Volume
11/09/26 CA$0.1100 -4.35% 83,100
10/09/26 CA$0.1150 +4.55% 1,474,300
09/09/26 CA$0.1100 +4.76% 120,785
08/09/26 CA$0.1050 -19.23% 398,041
  1. Stock Market
  2. Stocks
  3. AVCN Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!